Review Article

A Systematic Review of Ethanol and Fomepizole Use in Toxic Alcohol Ingestions

Table 2

Patient demographics; aggregate data.

DataVariable
Age
(years)
(mean ± SD)
Gender
(% male)
Time to diagnosis
(hours)
(mean ± SD)
Toxic alcohol level
(mmol/L)
(mean ± SD)
Ethanol Level
(mmol/L)
(mean ± SD)
pH
(mean ± SD)

Ethylene Glycol
 Fomepizole
  Cases (n = 31)42.5 ± 14.767%8.8 ± 7.246.2 ± 58.98.2 ± 13.67.16 ± 0.21
  Brent 1999 (n = 19)41 ± 1389%6.6–20.83.87–71.850–39.36.93–7.47
  Megarbane 2008 (n = 15)31 (27–51)83%PO: 1.0 ± 11.3
IV: 6.8 ± 53.5
 Ethanol
  Cases (n = 166)42.2 ± 14.384%5.3 ± 8.424.7 ± 43.920.3 ± 31.17.21 ± 0.22
  Karlson-Stiber 1992 (n = 32)20–696.7–7.4
  Hylander 1996 (n = 17)38 ± 1594%Alive: 33 ± 38.6
Dead: 8.7 ± 6.1
Alive: 7.2 ± 0.1
Dead: 6.9 ± 0.2
 Both
  Cases (n = 15)40.6 ± 15.480%13.3 ± 12.620.3 ± 16.807.18 ± 0.16

Methanol
 Fomepizole
  Cases (n = 72)44.9 ± 12.868%13.0 ± 10.743.8 ± 48.37.3 ± 18.67.16 ± 0.27
  Megarbane 2008 (n = 9)46 (38–55)83%PO: 3.12
IV: 7.49 ± 32.45
 Ethanol
  Cases (n = 201)39.0 ± 13.773%15.2 ± 17.263.0 ± 61.46.3 ± 12.37.13 ± 0.25
  Krishnamurthi 1968 (n = 89)87%
  Paasma 2007 (n = 111)Alive: 1.3–175  
Dead: 28.4–194.7  
Alive: 7.14
Dead: 6.78
  Moghadami 2008 (n = 62)31 ± 12.7100%8.49 ± 9.695.10 ± 6.10
  Taheri 2010 (n = 42)38 (15–81)93%48.6 (24–72)9.39 (6.86–20.9)6.9 (6.3–7.2)
  Cases (n = 18)43.7 ± 17.256%11.5 ± 13.958.3 ± 68.24.4 ± 10.57.26 ± 0.14
 Both
  Cases (n = 18)43.7 ± 17.256%11.5 ± 13.958.3 ± 68.24.4 ± 10.57.26 ± 0.14